Heart failure with preserved ejection fraction: future directions in medical treatment.

about

Heart failure with preserved ejection fraction: future directions in medical treatment.

Item

http://www.wikidata.org/entity/Q43965433

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Heart failure with preserved ejection fraction: future directions in medical treatment.

@en

Heart failure with preserved ejection fraction: future directions in medical treatment.

@nl

type

Item

label

Heart failure with preserved ejection fraction: future directions in medical treatment.

@en

Heart failure with preserved ejection fraction: future directions in medical treatment.

@nl

prefLabel

Heart failure with preserved ejection fraction: future directions in medical treatment.

@en

Heart failure with preserved ejection fraction: future directions in medical treatment.

@nl

P1476

Heart failure with preserved ejection fraction: future directions in medical treatment.

@en

P2093

Dimitrios M Konstantinou

http://www.w3.org/2001/XMLSchema#string

George D Giannoglou

http://www.w3.org/2001/XMLSchema#string

Yiannis S Chatzizisis

http://www.w3.org/2001/XMLSchema#string

P2860

Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction

Outcome of heart failure with preserved ejection fraction in a population-based study

Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure.

The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload.

Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes.

Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

Death in heart failure: a community perspective

Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

P304

1085-1087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/14779072.2013.824661

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23957908

http://www.w3.org/2001/XMLSchema#string